

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT  
Attorney Docket No.: 018623-008050US

Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

JAN 24 2000

On January 12, 2000

TOWNSEND and TOWNSEND and CREW LLP

By: Jennifer K. Hardin



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SETTE *et al.*

Application No.: 09/017,743

Filed: February 3, 1998

For: HLA BINDING PEPTIDES AND  
THEIR USES

Examiner: DiBrino, Marianne

Art Unit: 1644

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Box SEQUENCE  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Examiner's Communication mailed December 15, 1999, Applicants submit herewith the required paper copy and computer readable copy of the Substitute Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

IN THE SPECIFICATION:

Please cancel the present Sequence Listing and insert therefor the accompanying paper copy of the Substitute Sequence Listing, page numbers 1 to 37, at the end of the application.